Last updated: February 15, 2026
What is NDC 70700-0152?
NDC 70700-0152 is a prescription medication identified by the National Drug Code (NDC) as belonging to a specific drug product. Based on publicly available data, it likely refers to Ozempic (semaglutide), used for type 2 diabetes management, or another GLP-1 receptor agonist, but confirmation should be verified through official sources.
Market Landscape Overview
Size of the Market
The U.S. market for GLP-1 receptor agonists, including drugs like semaglutide, has grown steadily. In 2022, it reached approximately $12 billion, a compound annual growth rate (CAGR) of approximately 20% over the previous five years.
Key players include Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro). Novo Nordisk's Ozempic held around 60% of the GLP-1 market share as of 2022, reflecting its widespread adoption for diabetes and obesity indications.
Competitive Position
- Ozempic (semaglutide), marketed by Novo Nordisk, is a leading product with a strong brand presence.
- Eli Lilly's Mounjaro (tirzepatide) is a new competitor with promising efficacy and is expected to capture market share.
- Other drugs in the class include Dulaglutide (Trulicity) and Liraglutide (Victoza).
Regulatory Status
- Ozempic received FDA approval in December 2017 for type 2 diabetes management.
- The drug's label expanded to include weight management under Wegovy (also semaglutide) in June 2021.
- Patent protections extend into the late 2020s, with biosimilar competition expected by 2026.
Price Analysis
Current Pricing
Wholesale acquisition cost (WAC) and average sales price (ASP) provide insight into original pricing:
| Price Metric |
2022 Data |
Description |
| WAC |
~$850 |
Approximate per 4-week (monthly) retail price for Ozempic 0.5 mg |
| ASP |
~$720 |
Average price paid by payers, after discounts |
| Retail Price |
~$850–$880 |
Retail costs vary based on dosage and pharmacy benefits |
Cost Comparisons
| Product |
Approximate WAC |
Indications |
Dosing Schedule |
Notes |
| Ozempic |
~$850 |
Diabetes, obesity |
Weekly injections |
Budgeting based on 4-week supply |
| Mounjaro |
Not widely available yet |
Diabetes |
Weekly injections |
Potential price premium, pending launch data |
Price Projections
Factors influencing future pricing:
- Patent expirations and biosimilar entry: Expected around 2026, likely lowering prices.
- Manufacturing costs: Stable with potential reductions due to biosimilar competition.
- Market demand: Strong growth driven by expanding indications for weight management.
- Reimbursement policies: Payers focusing on value-based models might negotiate prices downward.
Short-term (Next 2 Years)
- Prices for NDC 70700-0152 are expected to stabilize within a 10-15% range of current levels, around $850–$950 for a monthly supply.
- Reimbursement and discounts might reduce net costs to providers/payers below list prices.
Long-term (3+ Years)
- Biosimilar entry around 2026 could lead to price decreases of 30-50% over current levels.
- Competition from Lilly’s Mounjaro may pressure pricing, especially if indications expand and market penetration accelerates.
Market Entry and Distribution Considerations
- Entry barriers remain high due to strong brand loyalty for established products.
- Distribution channels favor large payer agreements and specialty pharmacies.
- Direct-to-consumer marketing continues to enhance market penetration.
Key Takeaways
- Market for GLP-1 receptor agonists is expanding with a current valuation exceeding $12 billion.
- Current prices for NDC 70700-0152 are approximately $850 per month retail.
- The next two years will see relative price stability, with possible slight declines due to payer negotiations.
- Biosimilar competition projected to commence around 2026 could reduce prices by half.
- Competitive dynamics with Eli Lilly's Mounjaro could influence future price trajectories.
FAQs
1. When are biosimilars for semaglutide expected?
Biosimilars are projected for approval around 2026, based on patent expiry timelines.
2. How does Mounjaro compare price-wise to Ozempic?
Initial pricing for Mounjaro is expected to be similar to or slightly higher than Ozempic, but actual market prices depend on negotiated discounts.
3. What factors might influence price reductions?
Biosimilar market entry, increased competition, and payer negotiations can lower prices.
4. Are discounts significant in this market?
Yes, discounts from list prices can range from 10% to 30% depending on contracts and insurance plans.
5. How might evolving indications affect pricing?
Wider indications, such as weight management, can sustain higher prices due to increased demand.
Sources
- Evaluate Pharma, "GLP-1 receptor agonist market size and forecast," 2022.
- IQVIA, "Pharmaceutical Market Data," 2022.
- FDA Approvals and Label Updates, 2017-2022.
- Novo Nordisk financial reports, 2022.
- Earnings calls, analyst reports, 2022-2023.
